Abstract
Objective
The optimal timing of P2Y12 inhibitors in patients with acute ST-segment elevation myocardial infarction (STEMI) is still controversial. In our study, the effect of loading in the emergency department or catheterization laboratory on in-hospital and 1-month mortality in patients presenting with STEMI was investigated.
Material and Methods
The study included 252 patients who first presented to the emergency department with acute STEMI and were treated with primary percutaneous coronary interventio (PCI) within the first 12 hours after the onset of symptoms. The patients were divided into 2 groups as those who underwent P2Y12 inhibitors loading in the emergency department (group 1) and those who underwent P2Y12 inhibitors loading after coronary anatomy was determined in cathater laboratory (group 2) (group 1: 154 patients, 110 males, 57.1±12.4 years, group 2: 98 patients, 78 males, 58.2±12.3 years). In addition to 300 mg acetylsalicylic acid, the patients were loaded with 180 mg ticagrelor or 600 mg clopidogrel. Adverse cardiac outcomes were recorded as the need for re-PCI after the procedure, failure to open the infarct-related artery, intubation, requirement to a respiratory support device or exitus of the patient in the hospital and within the following 1 month.
Results
It was recorded that 22 patients resulted in exitus and 38 patients had adverse cardiac outcomes. Ticagrelor was loaded in 229 patients and clopidogrel was loaded in 23 patients who could not be loaded with ticagrelor. In 4 patients (2.6%) who were loaded in the emergency department and in 7 patients (7.1%) who were loaded in the catheterization laboratory, adequate flow (≥TIMI 2) could not be achieved in the infarct-related artery after the procedure (p=0.068). In patients with group 1, exitus and major adverse cardiovascular events numbers were significantly lower than in those loaded in the catheterization laboratory (6 vs. 16: p=0.001, 15 vs. 23: p=0.003).
Conclusion
In patients presenting with acute STEMI, P2Y12 inhibitors in the emergency department have a more positive effect on in-hospital and 1-month mortality and adverse endpoints compared to P2Y12 inhibitors in the catheterization laboratory.
Keywords: Acute ST segment elevation myocardial infarction, dual antiplatelet therapy, percutaneous coronary intervention, mortality
References
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177.
Ali M, Lange SA, Wittlinger T, Lehnert G, Rigopoulos AG, Noutsias M. Inhospital mortality after acute STEMI in patients undergoing primary PCI. Herz. 2018;43(8):741-745.
D’Ascenzo F, Barbero U, Moretti C, Plamerini T, Della Riva D, Mariani A, et al. Percutaneous coronary intervention versus coronary artery bypass graft for stable angina: meta-regression of randomized trials. Contemp Clin Trials. 2014;28:51-58.
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European Heart J. 2023;44:3720-3826.
Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention, 2011 ACCF/AHA Guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA Guideline for the Management of ST-elevation myocardial infarction, 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134:123-155.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. ESC/ACCF/AHA/WHF task force for the universal definition of myocardial infarction. Circulation. 2012;126(16):2020-2035.
Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213-260.
Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368(21):2004-2013.
Spronk HMH, Padro T, Siland JE, Prochaska JH, Winters J, van der Wal AC, et al. Atherothrombosis and thromboembolism: position paper from the Second Maastricht Consensus Conference on Thrombosis. Thromb Haemost 2018;118(02):229-250.
Trenk D, Hille L, Leggewie S, Stratz C, Nührenberg TG, Aradi D, et al. Antagonizing P2Y12 receptor inhibitors: current and future options. Thromb Haemost. 2019;119(10):1606-1616.
Gorog DA, Geisler T. Platelet inhibition in acute coronary syndrome and percutaneous coronary intervention: insights from the past and present. Thromb Haemost. 2020;120(4):565-578.
ZeitouniM, KerneisM, Nafee T, Collet JP, Silvain J, Montalescot G. Anticoagulation in acute coronary syndrome-state of the art. Prog Cardiovasc Dis. 2018;60(4-5):508-513.
Montalescot G, Barragan P, Wıttenberg O, Ecollan P, Elhadad S, Villain P, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344(25):1895-1903.
Zeymer U, Arntz UZ, Mark B, Fichtlscherer S, Werner G, Schöller R, et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol. 2012;101(4):305-312.
Bellemain-Appaix A, O’Connor SA, Silvain J, Cucherat M, Beygui F, Barthelemy O, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA. 2012;308(23):2507-2516.
Yudi MB, Farouque O, Anddrianopoulos N, Ajani AE, Brennan A, Lefkovits J, et al. Pretreatment with dual antiplatelet therapy in patients with ST-elevation myocardial infarction. Catheter Cardiovasc Interv. 2018;92(2):98-105.
Montalescot G, van’t Hof AW, lapostolle F, Silvain J, Lassen JF, Bolognese L, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371(11):1016-1027.
Koul S, Smith JG, Götberg M, Omerovic E, Alfredsson J, Venetsanos D, et al. No benefit of ticagrelor pretreatment compared with treatment during percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2018;11(3):005528.
Danchin N, Puymirat E, Cayla G, Cottin Y, Coste P, Gilard M, et al. One-year survival after ST-segment-elevation myocardial infarction in relation with prehospital administration of dual antiplatelet therapy. Circ Cardiovasc Interv. 2018;11(9):e007241.
Firman D, Taslim I, Wangi SB, Yonas E, Pranata R, Alkatiri AA. The effect of early dual antiplatelet timing on the microvascular resistance and ventricular function in primary percutaneous coronary intervention. Medicine (Baltimore). 2020;99(29):21177.
